|
Waldenstrom Macroglobulinemia
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 L265P was absent in paired normal tissue samples from patients with Waldenström's macroglobulinemia or non-IgM LPL and in B cells from healthy donors and was absent or rarely expressed in samples from patients with multiple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.
|
22931316 |
2012 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.
|
22944768 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
SomaticCausalMutation
|
disease |
ORPHANET |
MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.
|
23321251 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The finding of this mutation in many IgM MGUS patients suggests that MYD88 L265P may be an early oncogenic event in WM pathogenesis.
|
23321251 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
MYD88 (L265P) was detected in 58/58 (100%) patients with WM, 36/77 (47%) with IgM-MGUS, 5/84 (6%) with SMZL, and 3/52 (4%) with B-CLPD.
|
23355535 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among WM and IgM-MGUS, MYD88 L265P mutation was associated with some differences in clinical and biological characteristics, although usually minor; wild-type MYD88 cases had smaller M-component (1.77 vs 2.72 g/dl, P=0.022), more lymphocytosis (24 vs 5%, P=0.006), higher lactate dehydrogenase level (371 vs 265 UI/L, P=0.002), atypical immunophenotype (CD23-CD27+ +FMC7+ +), less Immunoglobulin Heavy Chain Variable gene (IGHV) somatic hypermutation (57 vs 97%, P=0.012) and less IGHV3-23 gene selection (9 vs 27%, P=0.014).
|
23446312 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Beyond the discovery of the myeloid differentiation primary response gene 88 (MYD88) L265P mutation, which will help greatly in the differential characterization of WM from other B-cell low-grade lymphomas, several other mechanisms of gene deregulation were identified and mapped that recurrently pointed out nuclear factor-kappa B (NF-κB), breakpoint cluster region (BCR), and Toll-like receptor (TLR) signaling pathways as potential targets for a better understanding of the physiopathology of WM and for future drug development.
|
23473949 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Abnormalities that affect myeloid differentiation primary response 88 (MYD88)--interleukin-1 receptor-associated kinase 4 (IRAK4) and nuclear factor kappa B (NF-κB) signaling pathways were found in a significant proportion of WM cases, which suggest their relevance in the pathogenesis of the disease and opening new avenues that may be a guide to design novel therapeutic approaches.
|
23477936 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
SomaticCausalMutation
|
disease |
ORPHANET |
MYD88 L265P mutation in Waldenstrom macroglobulinemia.
|
23532735 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with absence of MYD88 mutation were WM characterized with a female predominance, a splenomegaly, gain of chromosome 3, and CD27 expression.
|
23532735 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
A new era for Waldenstrom macroglobulinemia: MYD88 L265P.
|
23723443 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The results establish BTK as a downstream target of MYD88 L265P signaling, and provide a framework for the study of BTK inhibitors alone, and in combination with IRAK inhibitors for the treatment of WM.
|
23836557 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although not entirely specific, MYD88 L265P is a useful adjunct for bone marrow diagnosis in separating LPL from other small B-cell lymphomas and plasma cell myeloma.
|
23955458 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The absence of plasmacytoid cells, the presence of plasma cells predominantly outside the nodular lymphoid infiltrates, IGHV4-34 restriction and absence of MYD88 L265P mutation strongly suggest that cold agglutinin-associated lymphoproliferative disease is a distinct entity that is different from lymphoplasmacytic lymphoma.
|
24143001 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although the absence of the MyD88 L265P somatic mutation in our SS cohort does not exclude a common germline susceptibility gene in SS, it might suggest a distinct operating pathogenetic mechanism in SS-related lymphoma compared with WM and other hematological malignancies.
|
24153350 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.
|
24224040 |
2013 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
|
24366360 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These studies show the feasibility for detecting MYD88 L265P by PB examination, and the potential for PB MYD88 L265P ΔCt use in the diagnosis and management of WM patients.
|
24509637 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
Biomarker
|
disease |
BEFREE |
Targeted therapies directed against MYD88 and/or CXCR4 signaling may provide a personalized treatment approach to WM.
|
24553177 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This review discusses the role of MYD88 L265P mutations as well as targets beyond MYD88 in the setting of pathogenesis and development of future rational therapeutic trials focusing on patients diagnosed with WM.
|
24573383 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
They include the V600E BRAF mutation in hairy cell leukemia, the L265P MYD88 mutation in Waldenström macroglobulinemia, the G17V RHOA mutation in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, not otherwise specified, and the Y640F//D661Y/V/H/I//N647I STAT3 mutations in T-cell large granular lymphocytic leukemia.
|
24689848 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The myeloid differentiation primary response gene (88) leucine to proline mutation was observed in 3 of 5 LPL, 1 of 2 FL, and 2 of 4 LGBCL-NOS patients.
|
24767771 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this issue of Blood, Treon and colleagues provide strong evidence that mutations in MYD88 and CXCR4 dictate clinical presentation and survival in Waldenström macroglobulinemia (WM).
|
24786453 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
An oncogenic gain-of-function mutation (L265P) in the human MYD88 gene has been found to be present in most cases of WM/LPL, yet is absent in most other cases of B-cell chronic lymphoproliferative disorders (LPD), including SMZL.
|
24842316 |
2014 |